Research news Mouse experiments have suggested that glucagon-like peptide-1 receptor agonists may reduce pulmonary fibrosis following a COVID-19 infection in people with type 2 diabetes, although researchers cautioned that the findings remain preliminary Glucagon-like peptide-1 (GLP-1) receptor agonists, already used to treat type 2 diabetes (T2DM) and obesity, may also help to reduce the risk of COVID-19-related lung scarring in people with T2DM, according to research in mouse models
For small molecules, this is well-established - it's the basis of nicotine patches, hormone replacement patches, and prescription pain patches
When to Seek Medical Advice for Bruising A lot of people think they bruise easily
Many people now live for at least 5 years after their initial diagnosis
.,
Sanjay Bharti, MD , offers GLP-1 therapy for medical weight loss in Fairmont, WV